Copyright
©The Author(s) 2024.
World J Gastroenterol. Mar 21, 2024; 30(11): 1545-1555
Published online Mar 21, 2024. doi: 10.3748/wjg.v30.i11.1545
Published online Mar 21, 2024. doi: 10.3748/wjg.v30.i11.1545
Table 3 Quality of life data from the Short Form-36 questionnaire on the intention-to-treat analysis
| Item | Placebo arm | AN-PEP arm | ||
| At baseline | Final | At baseline | Final | |
| Number of patients | 21 | 19 | ||
| General health | ||||
| Median score (IQR) | 65 (50-72) | 70 (50-80)b | 50 (35-75) | 50 (40-80) |
| Pain | ||||
| Median score (IQR) | 80 (42-90) | 90 (50-80)b | 80 (45-90) | 67.5 (47.5-90.0)a |
| Vitality | ||||
| Median score (IQR) | 60 (45-65) | 60 (50-70) | 40 (30-60) | 55 (40-65)c |
| Mental health | ||||
| Median score (IQR) | 68 (52-72) | 68 (56-80) | 68 (40-72) | 64 (48-80) |
| Physical function | ||||
| Median score (IQR) | 95 (75-100) | 95 (75-100) | 95 (85-100) | 100 (90-100) |
| Social function | ||||
| Median score (IQR) | 75 (50-100) | 100 (62.5-100.0) | 50 (37-100) | 75 (50-100) |
| Physical limitations | ||||
| Median score (IQR) | 100 (50-100) | 100 (75-100) | 100 (25-100) | 75 (25-100) |
| Emotional limitations | ||||
| Median score (IQR) | 50 (0-100) | 100 (66-100)b | 66.7 (0-100) | 66.7 (0-100) |
- Citation: Stefanolo JP, Segura V, Grizzuti M, Heredia A, Comino I, Costa AF, Puebla R, Temprano MP, Niveloni SI, de Diego G, Oregui ME, Smecuol EG, de Marzi MC, Verdú EF, Sousa C, Bai JC. Effect of Aspergillus niger prolyl endopeptidase in patients with celiac disease on a long-term gluten-free diet. World J Gastroenterol 2024; 30(11): 1545-1555
- URL: https://www.wjgnet.com/1007-9327/full/v30/i11/1545.htm
- DOI: https://dx.doi.org/10.3748/wjg.v30.i11.1545